Indoline

Indoline

SCHEMBL22344762

N#Cc1ccc2c(c1)NCC2.c1ccc2c(c1)CCN2

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.47
DRD3 P35462 4/20 0.47
PNMT P11086 1/20 0.47
TRPA1 O75762 1/20 0.40
DRD4 P21917 1/20 0.40
ALDH1A1 P00352 1/20 0.38
GRM5 P41594 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDPK1 O15530 1/20 0.36
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
KDM1A O60341 1/20 0.36
HTR2C P28335 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL748146 0.91 PNMT (0.55) DRD2DRD3PNMTDRD4GFER
Hydrochloric Acid SCHEMBL28026444 0.90 PNMT (0.53) DRD2DRD3PNMTDRD4GFER
Indoline SCHEMBL28096138 0.82 ALDH1A1 (0.49) DRD2PNMTDRD4ALDH1A1KDM4E
Indoline SCHEMBL9132798 0.82 HTR2C (0.50) DRD2PNMTDRD4ALDH1A1KDM4E
SCHEMBL14732500 0.81 MAPT (0.57) DRD2DRD3PNMTTRPA1ALDH1A1
SCHEMBL30480861 0.81 PNMT (0.47) DRD2DRD3PNMTALDH1A1KDM4E
SCHEMBL17785608 0.81 PNMT (0.47) DRD2DRD3PNMTALDH1A1KDM4E
SCHEMBL288540 0.80 DRD2 (0.55) DRD2DRD3PNMTDRD4GRM5
Indoline SCHEMBL10798458 0.80 ALDH1A1 (0.43) DRD2PNMTDRD4ALDH1A1KDM4E
Indoline SCHEMBL9400596 0.80 DRD2 (0.46) DRD2DRD3PNMTDRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 US disclosed
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2022-04-21 US disclosed
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2022-02-15 US disclosed
US-20200262844-A1 ROCK KINASE INHIBITORS CERVELLO THERAPEUTICS, LLC. 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248004-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT DRD2 3508/4885DRD3 3580/4885PNMT 1154/4885
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT DRD2 3508/4885DRD3 3580/4885PNMT 1154/4885
US-20200262844-A1 ROCK KINASE INHIBITORS ROCK1, ROCK2, RHOA DRD2 4722/4885DRD3 4587/4885PNMT 2570/4885
US-20220119406-A1 SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS ROCK1, ROCK2, CIT DRD2 3508/4885DRD3 3580/4885PNMT 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.